carthera.eu

Avaliação do site carthera.eu

Home - Carthera

 Gerado a 09 de Abril de 2026 01:59 AM

Estatísticas desatualizadas? ATUALIZE !

O resultado é de 61/100

Conteúdo SEO

Título

Home - Carthera

Cumprimento : 15

Perfeito, o Título contém entre 10 e 70 caracteres.

Descrição

Revolutionizing severe brain disease treatments

Cumprimento : 47

Idealmente, a Descrição META deve conter entre 70 e 160 caracteres (incluíndo espaços).

Palavras-chave

Mau. Não detetámos palavras-chave META na sua página.

Propriedades Og Meta

Boa! Esta página tira vantagens das propriedades Og.

Propriedade Conteúdo
locale en_US
locale:alternate fr_FR
type website
title Home - Carthera
description Revolutionizing severe brain disease treatments
url https://carthera.eu/
site_name Carthera

Cabeçalhos

H1 H2 H3 H4 H5 H6
1 5 73 0 0 0
  • [H1] GLIOBLASTOMA and CNS DISEASES Revolutionizingbrain treatments
  • [H2] CARTHERA In a few figures
  • [H2] NO BRAIN DISEASE beyond reach
  • [H2] CLINICAL NEED AND SOLUTION Overcoming the BBB
  • [H2] Our latest news
  • [H2] AGENDA Our events
  • [H3] Our team
  • [H3] Indications
  • [H3] Strategy
  • [H3] Our ambition
  • [H3] Dynamic release of extracellular particles after opening of the blood-brain barrier predicts glioblastoma susceptibility to paclitaxel
  • [H3] Repeated blood−brain barrier opening using low-intensity pulsed ultrasound mitigates amyloid pathology
  • [H3] Carthera receives EMA expert panel endorsement for Orphan Medical Device status of SonoCloud® system
  • [H3] Carthera reaches recruitment milestone in SONOBIRD pivotal trial for recurrent glioblastoma
  • [H3] Pharmacokinetic Analysis of Carboplatin and Fluorescein Brain Retention following Ultrasound-Based Blood–Brain Barrier Opening
  • [H3] Effects of blood-brain barrier opening using ultrasound on tauopathies: A systematic review
  • [H3] Using ultrasound technology to open the blood brain barrier
  • [H3] Endothelial response to blood-brain barrier disruption in the human brain
  • [H3] Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound- mediated BBB opening: A novel combinatorial immunotherapy regimen for gliomas
  • [H3] Effect of ultrasound-mediated blood-spinal cord barrier opening on survival and motor function in females in an ALS mouse model
  • [H3] Carthera receives positive opinion from French High Authority for Health on Innovation Funding scheme to treat patients with recurrent glioblastoma
  • [H3] Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomas
  • [H3] Carthera receives Orphan Drug Designation (ODD) from US and EU authorities for carboplatin in malignant glioma
  • [H3] Paclitaxel and Carboplatin in Combination with Low-Intensity Pulsed Ultrasound for Glioblastoma
  • [H3] Carthera partners with Agenus and Northwestern University for phase 2a trial combining SonoCloud-9® with checkpoint inhibitors to treat glioblastoma
  • [H3] Positive results from phase I/II clinical trial of SonoCloud-9® in treatment of glioblastoma published in Nature Communications
  • [H3] Repeated blood–brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I/II clinical trial
  • [H3] Carthera enrolls first patient in pivotal trial of SonoCloud-9® device for treatment of recurrent glioblastoma
  • [H3] Series B round reaches €42M
  • [H3] Carthera signs strategic collaboration with Accord Healthcare
  • [H3] Repeated blood–brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase I clinical trial
  • [H3] Evaluating drug delivery enhancement following ultrasound treatment
  • [H3] Advances in Blood-Brain Barrier Disruption to Facilitate Drug Delivery for Infiltrative Gliomas
  • [H3] Carthera appoints Dr. Oern Stuge as chairman of board of directors
  • [H3] Childhood Brain Tumors: A Review of Strategies to Translate CNS Drug Delivery to Clinical Trials
  • [H3] Low-Intensity Pulsed Ultrasound-Mediated Blood-Brain Barrier Opening Increases Anti-Programmed Death-Ligand 1 Delivery and Efficacy in Gl261 Mouse Model
  • [H3] Carthera closes €37.5M Series B funding round
  • [H3] Promising results from SonoCloud-9 clinical trial in combination with nab-paclitaxel have been published in Lancet Oncology
  • [H3] Carthera announces positive outcome of End-of-Phase 2 meeting with FDA for SonoCloud-9 system for treatment of recurrent glioblastoma
  • [H3] Carthera receives FDA Breakthrough Device Designation for SonoCloud-9 system
  • [H3] Pilot study of repeated blood-brain barrier disruption in patients with mild Alzheimer's disease
  • [H3] Opening of the Blood-Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models
  • [H3] SonoCloud® technology enhances the efficacy of immunotherapies for the treatment of brain tumor.
  • [H3] Launch of a new phase I/IIclinical trial in collaboration with Northwestern University in Chicago
  • [H3] Carthera receive €2M grant and €10.5M equity from the European Innovation Council
  • [H3] First patient enrolled in new clinical trial for SonoCloud technology in melanoma
  • [H3] Ultrasound-induced blood-brain barrier disruption for the treatment of gliomas and other primary CNS tumors
  • [H3] Blood–brain barrier opening with low intensity pulsed ultrasound for immune modulation and immune therapeutic delivery to CNS tumors
  • [H3] Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations
  • [H3] Blood-brain barrier disruption with low-intensity pulsed ultrasound for the treatment of pediatric brain tumors: a review and perspectives
  • [H3] Study of the means to characterize the opening of the blood-brain barrier induced by an implantable ultrasound device
  • [H3] Strategic collaboration with US-based company Lantheus
  • [H3] Latest data from the SonoCloud-9 clinical study presented at SNO on November 20-24, 2019
  • [H3] Collaboration with KIYATEC in effort to bring personalized medicine to patients stricken by brain cancer
  • [H3] FDA approval to launch a Phase 1/2a trial in glioblastoma
  • [H3] Pascal Girin, new chairman of the Board of Directors
  • [H3] Temporary blood–brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma
  • [H3] Publishing of complete results of Phase I/IIa clinical trial using the SonoCloud-1 ultrasound implant
  • [H3] Safety and Feasibility of Repeated and Transient Blood–Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma
  • [H3] Blood-brain barrier disruption in humans using an implantable ultrasound device: quantification with MR images and correlation with local acoustic pressure
  • [H3] ANSM approval to launch a phase I-II clinical trial for the SonoCloud-9 device
  • [H3] Closing of a €9M ($10.3M) Series B funding round
  • [H3] Potentialisation des chimiothérapies dans le traitement du glioblastome : étude des transporteurs ABC et ouverture de la barrière hémato-encéphalique par ultrasons
  • [H3] Capacitive Micro-machined Ultrasound Transducers for Interstitial High Intensity Ultrasound Therapies
  • [H3] Blood-brain barrier, cytotoxic chemotherapies and glioblastoma
  • [H3] Safe long-term repeated disruption of the blood-brain barrier using an implantable ultrasound device: a multiparametric study in a primate mod
  • [H3] Clinical trial of blood-brain barrier disruptionby pulsed ultrasound
  • [H3] Enhanced brain distribution ofcarboplatin ina primate model afterblood–brain barrier disruption using an implantable ultrasound device
  • [H3] Ultrasound-induced opening of the blood-brain barrier to enhance temozolomide and irinotecan delivery: an experimental study in rabbits
  • [H3] A multi-element interstitial ultrasound applicator for the thermaltherapy of brain tumors
  • [H3] Opening of the blood-brain barrier with an unfocused ultrasound device in rabbits
  • [H3] 30th Annual Meeting of SNO, Society for Neuro-Oncology
  • [H3] 20th Annual Meeting of EANO, European Association of Neuro-Oncology
  • [H3] Congress of Neurological Surgeons (CNS)
  • [H3] Annual Congress of EANS, European Association of Neurosurgical societies
  • [H3] 24th Annual International Symposium on Therapeutic Ultrasound (ISTU)
  • [H3] Annual meeting of ANOCEF, Association des Neuro-oncologues d'Expression Française
  • [H3] Brain Tumor Biotech Day
  • [H3] NMN symposium, Nuclear medecine and Neuro-Oncology

Imagens

Encontrámos 102 imagens nesta página.

71 atributos ALT estão vazios ou em falta. É recomendado adicionar texto alternativo de modo a que os motores de busca identifiquem melhor o conteúdo das suas imagens.

Rácio Texto/HTML

Rácio : 31%

Ideal! O rácio de texto para código HTML desta página está entre 25 e 70 porcento.

Flash

Perfeito, não foi encontrado conteúdo Flash nesta página.

Iframe

Oh, não, esta página tem Iframes na página, o que significa que o conteúdo destas não pode ser indexado.

Reescrita de URL

Perfeito. As ligações aparentam ser limpas!

Underscores (traços inferiores) nas URLs

Perfeito. Não foram encontrados 'underscores' (traços inferiores) nas suas URLs.

Ligações para a própria página

Encontrámos um total de 10 ligações incluindo 0 ligações a ficheiros

Âncoras Tipo Sumo
About Us Internas Passa sumo
Our Solutions Internas Passa sumo
Research & Development Internas Passa sumo
Our News Internas Passa sumo
Legal Mentions & Disclaimer Internas Passa sumo
Privacy Policy Internas Passa sumo
U.S. Expanded Access Policy Internas Passa sumo
Sitemap Internas Passa sumo
Contact (EN) Internas Passa sumo
Kookline Externas Passa sumo

Palavras-chave SEO

Núvem de palavras-chave

publication read glioblastoma more ultrasound request scientific barrier brain carthera

Consistência das Palavras-chave

Palavra-chave Conteúdo Título Palavras-chave Descrição Cabeçalhos
publication 69
scientific 34
carthera 32
request 32
brain 32

Usabilidade

Url

Domínio : carthera.eu

Cumprimento : 11

Favicon

Ótimo, o site tem um favicon.

Facilidade de Impressão

Não encontrámos CSS apropriado para impressão.

Língua

Otimo! A língua declarada deste site é en.

Dublin Core

Esta página não tira vantagens do Dublin Core.

Documento

Tipo de Documento

HTML 5

Codificação

Perfeito. O conjunto de caracteres UTF-8 está declarado.

Validação W3C

Erros : 0

Avisos : 0

Privacidade do Email

Aviso! No mínimo, foi encontrado um endereço de email sob a forma de texto. Isto é um convite para que spammers entupam a caixa de correio deste endereço.

HTML obsoleto

Fantástico! Não detetámos etiquetas HTML obsoletas.

Dicas de Velocidade

Excelente, este site não usa tablelas dentro de tabelas.
Oh não, o site usa estilos CSS nas etiquetas HTML.
Boa, o site usa poucos ficheiros CSS.
Perfeito, o site usa poucos ficheiros JavaScript.
Perfeito, o site tira vantagens da compressão gzip.

Dispositivos Móveis

Otimização para dispositivos móveis

Icon Apple
Meta Viewport Tag
Conteúdo Flash

Otimização

XML Sitemap

Perfeito, o site tem um mapa XML do site (sitemap).

https://carthera.eu/sitemap_index.xml

Robots.txt

https://carthera.eu/robots.txt

Perfeito, o seu site tem um ficheiro robots.txt.

Analytics

Em falta

Não detetámos nenhuma ferramenta analítica de análise de atividade.

Este tipo de ferramentas (como por exemplo o Google Analytics) permite perceber o comportamento dos visitantes e o tipo de atividade que fazem. No mínimo, uma ferramenta deve estar instalada, sendo que em algumas situações mais do que uma pode ser útil.

PageSpeed Insights

Dispositivo
Categorias

Free SEO Testing Tool

Free SEO Testing Tool é uma ferramenta gratuita que o ajuda a avaliar o seu site